MOJ
eISSN: 2575-9094
Submit manuscript...
Review Article Volume 3 Issue 1
Are we at the verge of finding a new efficacious pharmacotherapy for obesity in the form of agonism at triple drug receptors: glucagon, Glucagon like peptide1 (GLP1), glucose dependent insulin tropic peptide (GIP)
Kulvinder Kochar Kaur, Gautam Allahbadia, Mandeep Singh
Received: November 12, 2018 | Published: February 18, 2019
Citation: Kaur KK, Allahbadia G, Singh M. Are we at the verge of finding a new efficacious pharmacotherapy for obesity in the form of agonism at triple drug receptors: glucagon, Glucagon like peptide1 (GLP1), glucose dependent insulin tropic peptide (GIP). Int Phys Med Rehab J. 2019;3(1):22-27. DOI: 10.15406/mojddt.2019.03.00075
Abstract
Obesity is becoming a worldwide pandemic, and it calls for concerted efforts to act in view of preventing it from becoming a menace. Since lifestyle interventions and exercise have proven to be not of much use by themselves with the weight loss getting defended by the obese brain, with the regained weight set point gets defended. Currently most pharmacotherapy do not offer a sustained weight loss and don’t have efficacy over 1-5kg loss for over 3-6mths.Till now the only drug having some promise are believed to be thylakoids. Although the most effective weight loss strategy remains bariatric surgery(BS),although its mechanism of action remains unclear though it is the most effective ,but indicated in limited cases with severe morbidly obese or those with BMI over 35kg with co morbidities. Further it has disadvantage of being costly and not available to all obese patients and is not without its inherent risks .Still it causes immediate remission of T2DM,and mediates sustained weight loss .Some proposed mechanism of action of BS is by acting through CNS and some other GIT hormones like GLP1, ghrelin PYY. Thus the new class of multiagonists drugs are trying to combine to form a single molecular drug which might try to close the gap, improving efficacy to improve the metabolism of the system. The drug constitutes a single drug in which agonism for the receptors of glucagon, glucagon like peptide1 (GLP1), glucose dependent insulunotropic polypeptide (GIP) is combined. In preclinical studies these multiagonists do better than their mono agonist counter parts. In clinical trials rigorous safety analysis are on the way and these drugs might be on the way in becoming the elusive pharmacotherapy for obesity. Currently the drugs offering most promise as medical therapies remain thylakoids, BAT directed therapies and with these drugs passing the test of time and human clinical trials might be the most superior multiagonists for the future hopefully
Keywords: BS; Glp1;GIP, Glucagon Dual and Triple Agonists; obesity; weight loss
©2019 Kaur, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.